Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Phase II Trial of Sacituzumab Govitecan for Patients with HER2-Negative Breast Cancer and Brain Metastases. Open to HR+ and HR- patients. Progression of disease after CNS directed therapy or before CNS directed therapy. Evidence of crossing of blood brain barrier with this agent.

Open to HR+ and HR- patientsProgression of disease after CNS directed therapy or before CNS directed therapy. Evidence of crossing of blood brain barrier with this agent.

Learn More at  ClinicalTrials.gov

Contact 310-582-7448 to participate.